by nobilistx | Mar 27, 2022 | Uncategorized |
Nobilis therapeutics is pleased to report that the validation formalities for the European patent it has licensed from MassGeneral Brigham have now been completed in France, Germany, Greece, Italy, the Netherlands, Portugal and the United Kingdom. The patent that has...
by nobilistx | Mar 27, 2022 | Uncategorized |
CCONNECTpreneur is one of the largest investor communities that has helped raise billions of dollars for startups and more established businesses. Nobilis Therapeutis is proud to be selected to present at this event and looks forward to sharing its...
by nobilistx | Sep 29, 2021 | Uncategorized |
Company is expanding its pipeline to create effective treatment for opioid addiction PORTLAND, ORE. (EINPRESSWIRE) September 29, 2021 Nobilis Therapeutics, a clinical stage biotechnology company focused on advancement of innovative CNS therapies, announced today the...
by nobilistx | Jul 26, 2021 | Uncategorized |
Portland, OR — Nobilis Therapeutics is happy to announce its participation in Biotechgate Digital Partnering event that will take place on August 30 Aug – 3 Sep, 2021. Biotechgate Digital Partnering is designed to support the business development of Pharma,...
by nobilistx | Jun 14, 2021 | Uncategorized |
An article in the April 15th issue of the Journal of Experimental Pharmacology titled “Experimental Drugs for Panic Disorder: An Updated Systematic Review” has devoted a significant section to the discussion of Nobilis Therapeutics’ approach to the...
Recent Comments